FASLG and viral infectious disease: We, therefore, propose a longitudinal study, which will evaluate the activation of the CD95-CD95L signalling pathway during the progression of the viral infection, from cultures of hepatocytes infected with HBV, and which will evaluate the inhibition of CD95 receptors as an immunotherapeutic method in patients with chronic HBV.